Impact of antibiotics on gut microbiome composition and resistome in the first years of life in low- to middle-income countries: A systematic review.


Journal

PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360

Informations de publication

Date de publication:
06 2023
Historique:
received: 23 09 2022
accepted: 13 04 2023
medline: 29 6 2023
pubmed: 27 6 2023
entrez: 27 6 2023
Statut: epublish

Résumé

Inappropriate antimicrobial usage is a key driver of antimicrobial resistance (AMR). Low- and middle-income countries (LMICs) are disproportionately burdened by AMR and young children are especially vulnerable to infections with AMR-bearing pathogens. The impact of antibiotics on the microbiome, selection, persistence, and horizontal spread of AMR genes is insufficiently characterized and understood in children in LMICs. This systematic review aims to collate and evaluate the available literature describing the impact of antibiotics on the infant gut microbiome and resistome in LMICs. In this systematic review, we searched the online databases MEDLINE (1946 to 28 January 2023), EMBASE (1947 to 28 January 2023), SCOPUS (1945 to 29 January 2023), WHO Global Index Medicus (searched up to 29 January 2023), and SciELO (searched up to 29 January 2023). A total of 4,369 articles were retrieved across the databases. Duplicates were removed resulting in 2,748 unique articles. Screening by title and abstract excluded 2,666 articles, 92 articles were assessed based on the full text, and 10 studies met the eligibility criteria that included human studies conducted in LMICs among children below the age of 2 that reported gut microbiome composition and/or resistome composition (AMR genes) following antibiotic usage. The included studies were all randomized control trials (RCTs) and were assessed for risk of bias using the Cochrane risk-of-bias for randomized studies tool. Overall, antibiotics reduced gut microbiome diversity and increased antibiotic-specific resistance gene abundance in antibiotic treatment groups as compared to the placebo. The most widely tested antibiotic was azithromycin that decreased the diversity of the gut microbiome and significantly increased macrolide resistance as early as 5 days posttreatment. A major limitation of this study was paucity of available studies that cover this subject area. Specifically, the range of antibiotics assessed did not include the most commonly used antibiotics in LMIC populations. In this study, we observed that antibiotics significantly reduce the diversity and alter the composition of the infant gut microbiome in LMICs, while concomitantly selecting for resistance genes whose persistence can last for months following treatment. Considerable heterogeneity in study methodology, timing and duration of sampling, and sequencing methodology in currently available research limit insights into antibiotic impacts on the microbiome and resistome in children in LMICs. More research is urgently needed to fill this gap in order to better understand whether antibiotic-driven reductions in microbiome diversity and selection of AMR genes place LMIC children at risk for adverse health outcomes, including infections with AMR-bearing pathogens.

Sections du résumé

BACKGROUND
Inappropriate antimicrobial usage is a key driver of antimicrobial resistance (AMR). Low- and middle-income countries (LMICs) are disproportionately burdened by AMR and young children are especially vulnerable to infections with AMR-bearing pathogens. The impact of antibiotics on the microbiome, selection, persistence, and horizontal spread of AMR genes is insufficiently characterized and understood in children in LMICs. This systematic review aims to collate and evaluate the available literature describing the impact of antibiotics on the infant gut microbiome and resistome in LMICs.
METHODS AND FINDINGS
In this systematic review, we searched the online databases MEDLINE (1946 to 28 January 2023), EMBASE (1947 to 28 January 2023), SCOPUS (1945 to 29 January 2023), WHO Global Index Medicus (searched up to 29 January 2023), and SciELO (searched up to 29 January 2023). A total of 4,369 articles were retrieved across the databases. Duplicates were removed resulting in 2,748 unique articles. Screening by title and abstract excluded 2,666 articles, 92 articles were assessed based on the full text, and 10 studies met the eligibility criteria that included human studies conducted in LMICs among children below the age of 2 that reported gut microbiome composition and/or resistome composition (AMR genes) following antibiotic usage. The included studies were all randomized control trials (RCTs) and were assessed for risk of bias using the Cochrane risk-of-bias for randomized studies tool. Overall, antibiotics reduced gut microbiome diversity and increased antibiotic-specific resistance gene abundance in antibiotic treatment groups as compared to the placebo. The most widely tested antibiotic was azithromycin that decreased the diversity of the gut microbiome and significantly increased macrolide resistance as early as 5 days posttreatment. A major limitation of this study was paucity of available studies that cover this subject area. Specifically, the range of antibiotics assessed did not include the most commonly used antibiotics in LMIC populations.
CONCLUSION
In this study, we observed that antibiotics significantly reduce the diversity and alter the composition of the infant gut microbiome in LMICs, while concomitantly selecting for resistance genes whose persistence can last for months following treatment. Considerable heterogeneity in study methodology, timing and duration of sampling, and sequencing methodology in currently available research limit insights into antibiotic impacts on the microbiome and resistome in children in LMICs. More research is urgently needed to fill this gap in order to better understand whether antibiotic-driven reductions in microbiome diversity and selection of AMR genes place LMIC children at risk for adverse health outcomes, including infections with AMR-bearing pathogens.

Identifiants

pubmed: 37368871
doi: 10.1371/journal.pmed.1004235
pii: PMEDICINE-D-22-03191
pmc: PMC10298773
doi:

Substances chimiques

Anti-Bacterial Agents 0
Azithromycin 83905-01-5

Types de publication

Systematic Review Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1004235

Informations de copyright

Copyright: © 2023 Luchen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Nature. 2008 Oct 9;455(7214):804-7
pubmed: 18724361
Gut Microbes. 2016 Sep 2;7(5):443-9
pubmed: 27472377
Lancet. 2005 Feb 12-18;365(9459):579-87
pubmed: 15708101
Nature. 2005 Aug 25;436(7054):1157-60
pubmed: 16121181
Cell Host Microbe. 2018 Aug 8;24(2):197-207.e4
pubmed: 30092197
Lancet Infect Dis. 2020 Feb;20(2):179-187
pubmed: 31843383
World J Pediatr. 2019 Aug;15(4):390-397
pubmed: 30635840
PLoS One. 2016 Aug 25;11(8):e0161654
pubmed: 27560963
N Engl J Med. 2018 Apr 26;378(17):1583-1592
pubmed: 29694816
J Pediatr. 2015 Nov;167(5):1096-102.e3
pubmed: 26372535
Nat Rev Microbiol. 2007 Mar;5(3):175-86
pubmed: 17277795
Clin Infect Dis. 2017 May 1;64(9):1147-1153
pubmed: 28402408
EBioMedicine. 2018 Dec;38:265-272
pubmed: 30478001
Pediatrics. 2009 Mar;123(3):1003-10
pubmed: 19255032
Nat Med. 2019 Sep;25(9):1370-1376
pubmed: 31406349
Gut Microbes. 2021 Jan-Dec;13(1):1-18
pubmed: 33651651
N Engl J Med. 2019 Jun 06;380(23):2207-2214
pubmed: 31167050
Nat Microbiol. 2019 Dec;4(12):2285-2297
pubmed: 31501537
Front Microbiol. 2017 Jun 23;8:1162
pubmed: 28690602
Lancet. 2022 Feb 12;399(10325):629-655
pubmed: 35065702
Sci Rep. 2017 Aug 23;7(1):9168
pubmed: 28835659
Trends Microbiol. 2019 Feb;27(2):131-147
pubmed: 30529020
Gastroenterology. 2016 Jul;151(1):120-129.e5
pubmed: 27003602
J Med Microbiol. 2017 Sep;66(9):1297-1307
pubmed: 28855025
J Microbiol Biotechnol. 2017 Dec 28;27(12):2089-2093
pubmed: 29032640
Arch Oral Biol. 2020 Jun;114:104730
pubmed: 32371145
Elife. 2018 Dec 18;7:
pubmed: 30560781
Obes Rev. 2018 Nov;19(11):1463-1475
pubmed: 30035851
Open Forum Infect Dis. 2018 Nov 02;5(11):ofy289
pubmed: 30515431
Clin Microbiol Rev. 2015 Jul;28(3):565-91
pubmed: 25926236
BMC Infect Dis. 2017 Sep 11;17(1):616
pubmed: 28893183
N Engl J Med. 2020 Nov 12;383(20):1941-1950
pubmed: 33176084
JAMA. 2009 Sep 2;302(9):962-8
pubmed: 19724043
Clin Infect Dis. 2011 Apr 1;52(7):883-8
pubmed: 21427395
Clin Infect Dis. 2020 Dec 31;71(11):2858-2868
pubmed: 31832638
Lancet Infect Dis. 2018 Feb;18(2):e33-e44
pubmed: 29033034
Gut Pathog. 2022 Jan 6;14(1):5
pubmed: 34991704
Am J Trop Med Hyg. 2020 Sep;103(3):1266-1269
pubmed: 32524948
mBio. 2019 Dec 24;10(6):
pubmed: 31874917
Mucosal Immunol. 2022 May;15(5):1000-1011
pubmed: 35842561
BMJ. 2019 Aug 28;366:l4898
pubmed: 31462531
N Engl J Med. 2013 Jan 31;368(5):407-15
pubmed: 23323867
Gut Microbes. 2021 Jan-Dec;13(1):1-20
pubmed: 33535896
Nat Commun. 2022 Feb 16;13(1):893
pubmed: 35173154
Cell. 2014 Aug 14;158(4):705-721
pubmed: 25126780
Syst Rev. 2016 Dec 5;5(1):210
pubmed: 27919275
BMC Infect Dis. 2014 Jan 09;14:13
pubmed: 24405683
Lancet Planet Health. 2021 Dec;5(12):e893-e904
pubmed: 34774223
Lancet Glob Health. 2021 May;9(5):e610-e619
pubmed: 33713630
Microorganisms. 2019 Sep 18;7(9):
pubmed: 31540466
Nat Microbiol. 2020 Feb;5(2):304-313
pubmed: 31907407
Nat Rev Immunol. 2013 Nov;13(11):790-801
pubmed: 24096337
N Engl J Med. 2021 Apr 22;384(16):1517-1528
pubmed: 33826814
BMJ. 2014 Apr 15;348:g2267
pubmed: 24735883
Antibiotics (Basel). 2022 Mar 31;11(4):
pubmed: 35453221
Open Forum Infect Dis. 2018 Jul 24;5(8):ofy182
pubmed: 30151409
Pediatrics. 2018 Dec;142(6):
pubmed: 30381474
Clin Infect Dis. 2020 Jan 16;70(3):525-527
pubmed: 31149703
Cell Rep. 2022 Apr 12;39(2):110649
pubmed: 35417701
Front Microbiol. 2018 May 22;9:1037
pubmed: 29872428
N Engl J Med. 2016 Dec 15;375(24):2369-2379
pubmed: 27974040

Auteurs

Charlie C Luchen (CC)

Amsterdam UMC, location University of Amsterdam, Department of Global Health, Amsterdam Institute for Global Health and Development, Amsterdam, the Netherlands.
Research Division, Centre for Infectious Disease Research in Zambia, Lusaka, Zambia.
Amsterdam Institute of Infection and Immunity, Infectious Diseases, Amsterdam University Medical Center, Amsterdam, the Netherlands.

Mwelwa Chibuye (M)

Amsterdam UMC, location University of Amsterdam, Department of Global Health, Amsterdam Institute for Global Health and Development, Amsterdam, the Netherlands.
Research Division, Centre for Infectious Disease Research in Zambia, Lusaka, Zambia.
Amsterdam Institute of Infection and Immunity, Infectious Diseases, Amsterdam University Medical Center, Amsterdam, the Netherlands.

Rene Spijker (R)

Amsterdam UMC, location University of Amsterdam, Department of Global Health, Amsterdam Institute for Global Health and Development, Amsterdam, the Netherlands.

Michelo Simuyandi (M)

Research Division, Centre for Infectious Disease Research in Zambia, Lusaka, Zambia.

Caroline Chisenga (C)

Research Division, Centre for Infectious Disease Research in Zambia, Lusaka, Zambia.

Samuel Bosomprah (S)

Research Division, Centre for Infectious Disease Research in Zambia, Lusaka, Zambia.
Department of Biostatistics, School of Public Health, University of Ghana, Accra, Ghana.

Roma Chilengi (R)

Research Division, Centre for Infectious Disease Research in Zambia, Lusaka, Zambia.
Zambia National Public Health Institute, Ministry of Health, Lusaka, Zambia.
Republic of Zambia State House, Lusaka, Zambia.

Constance Schultsz (C)

Amsterdam UMC, location University of Amsterdam, Department of Global Health, Amsterdam Institute for Global Health and Development, Amsterdam, the Netherlands.
Amsterdam Institute of Infection and Immunity, Infectious Diseases, Amsterdam University Medical Center, Amsterdam, the Netherlands.
Amsterdam UMC, location University of Amsterdam, Department of Medical Microbiology, Amsterdam, the Netherlands.

Daniel R Mende (DR)

Amsterdam Institute of Infection and Immunity, Infectious Diseases, Amsterdam University Medical Center, Amsterdam, the Netherlands.
Amsterdam UMC, location University of Amsterdam, Department of Medical Microbiology, Amsterdam, the Netherlands.

Vanessa C Harris (VC)

Amsterdam UMC, location University of Amsterdam, Department of Global Health, Amsterdam Institute for Global Health and Development, Amsterdam, the Netherlands.
Amsterdam Institute of Infection and Immunity, Infectious Diseases, Amsterdam University Medical Center, Amsterdam, the Netherlands.
Amsterdam UMC, location University of Amsterdam, Department of Internal Medicine, Division of Infectious Diseases, Amsterdam, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH